Improving Mycobacterium bovis bacillus calmette-Guèrin as a vaccine delivery vector for viral antigens by incorporation of glycolipid activators of NKT cells

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Venkataswamy, Manjunatha M ^a,b   Ng, Tony W ^a   Kharkwal, Shalu S ^a   Carreño, Leandro J ^a,c   Johnson, Alison J ^a   Kunnath Velayudhan, Shajo ^a   Liu, Zheng ^d   Bittman, Robert ^d   Jervis, Peter J ^e   Cox, Liam R ^e   Besra, Gurdyal S ^e   Wen, Xiangshu ^f   Yuan, Weiming ^f   Tsuji, Moriya ^g   Li, Xiangming ^g   Ho, David D ^g   Chan, John ^a   Lee, Sunhee ^h   Frothingham, Richard ^h   Haynes, Barton F ^h   Panas, Michael W ^i,j   Gillard, Geoffrey O ^i,k   Sixsmith, Jaimie D ⁱ   Korioth Schmitz, Birgit ⁱ   Schmitz, Joern E ⁱ   Larsen, Michelle H ^a   Jacobs, William R ^a   Porcelli, Steven A ^a   more..

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b NATIONAL INSTITUTE OF MENTAL HEALTH AND NEUROSCIENCES   (India)

^c UNIVERSITY OF CHILE   (Chile)

^d CITY UNIVERSITY OF NEW YORK   (United States)

^e UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^f UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^g AARON DIAMOND AIDS RESEARCH CENTER   (United States)

^h DUKE UNIVERSITY MEDICAL CENTER   (United States)

ⁱ BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^j STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k BIOGEN   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; BCG VACCINE; CD1D ANTIGEN; EPITOPE; GAG PROTEIN; GLYCOLIPID; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOLOGICAL ADJUVANT; PLACEBO; ALPHA-GALACTOSYLCERAMIDE; GALACTOSYLCERAMIDE; VIRUS ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CROSS PRESENTATION; DRUG ADMINISTRATION ROUTE; DRUG FORMULATION; EXPRESSION VECTOR; FEMALE; GENE DELIVERY SYSTEM; IMMUNIZATION; IMMUNOGENICITY; IMMUNOSTIMULATION; MEMORY T LYMPHOCYTE; MOUSE; MOUSE MODEL; MYCOBACTERIUM BOVIS; NATURAL KILLER T CELL; NONHUMAN; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; T LYMPHOCYTE ACTIVATION; VIRUS PARTICLE; WILD TYPE; ANIMAL; CLONAL ANERGY; DISEASE MODEL; GENETICS; HUMAN; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; TRANSGENIC MOUSE;

MYCOBACTERIUM BOVIS;

ANIMALS; ANTIGENS, VIRAL; BCG VACCINE; CD8-POSITIVE T-LYMPHOCYTES; CLONAL ANERGY; DISEASE MODELS, ANIMAL; FEMALE; GALACTOSYLCERAMIDES; GENE PRODUCTS, GAG; GLYCOLIPIDS; HUMANS; IMMUNOLOGIC MEMORY; LYMPHOCYTE ACTIVATION; MICE; MICE, TRANSGENIC; MYCOBACTERIUM BOVIS; NATURAL KILLER T-CELLS; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 84907478533     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0108383     Document Type: Article

References (51)

1. Chapman R, Chege G, Shephard E., Stutz H, Williamson A.L. (2010) Recombinant Mycobacterium bovis BCG as an HIV vaccine vector. Curr HIV Res 8: 282-298.
2. Bastos RG, Borsuk S, Seixas F.K., Dellagostin O.A. (2009) Recombinant Mycobacterium bovis BCG. Vaccine 27: 6495-6503.
3. Aldovini A, Young R.A. (1991) Humoral and cell-mediated immune responses to live recombinant BCG-HIV vaccines. Nature 351: 479-482.
4. Kameoka M, Nishino Y, Matsuo K., Ohara N, Kimura T, et al (1994) Cytotoxic T lymphocyte response in mice induced by a recombinant BCG vaccination which produces an extracellular alpha antigen that fused with the human immunodeficiency virus type 1 envelope immunodominant domain in the V3 loop. Vaccine 12: 153-158.
5. Lagranderie M, Winter N, Balazuc A.M., Gicquel B., Gheorghiu M. (1998) A cocktail of Mycobacterium bovis BCG recombinants expressing the SIV Nef, Env, and Gag antigens induces antibody and cytotoxic responses in mice vaccinated by different mucosal routes. AIDS Res Hum Retroviruses 14: 1625-1633.
6. Winter N, Lagranderie M, Gangloff S., Leclerc C, Gheorghiu M, et al (1995) Recombinant BCG strains expressing the SIVmac251nef gene induce proliferative and CTL responses against nef synthetic peptides in mice. Vaccine 13: 471-478.
7. Yasutomi Y, Koenig S, Haun S.S., Stover CK, Jackson RK, et al. (1993) Immunization with recombinant BCG-SIV elicits SIV-specific cytotoxic T lymphocytes in rhesus monkeys. J Immunol 150: 3101-3107.
8. Ami Y, Izumi Y, Matsuo K., Someya K, Kanekiyo M, et al (2005) Priming-boosting vaccination with recombinant Mycobacterium bovis bacillus Calmette-Guerin and a nonreplicating vaccinia virus recombinant leads to long-lasting and effective immunity. J Virol 79: 12871-12879.
9. Cayabyab MJ, Korioth-Schmitz B, Sun Y., Carville A, Balachandran H, et al (2009) Recombinant Mycobacterium bovis BCG prime-recombinant adenovirus boost vaccination in rhesus monkeys elicits robust polyfunctional simian immunodeficiency virus-specific T-cell responses. J Virol 83: 5505-5513.
10. Hopkins R, Bridgeman A, Bourne C., Mbewe-Mvula A, Sadoff JC, et al (2011) Optimizing HIV-1-specific CD8+ T-cell induction by recombinant BCG in prime-boost regimens with heterologous viral vectors. Eur J Immunol 41: 3542-3552.
11. Rosario M, Bridgeman A, Quakkelaar E.D., Quigley MF, Hill BJ, et al. (2010) Long peptides induce polyfunctional T cells against conserved regions of HIV-1 with superior breadth to single-gene vaccines in macaques. Eur J Immunol 40: 1973-1984.
12. Dennehy M, Williamson A.L. (2005) Factors influencing the immune response to foreign antigen expressed in recombinant BCG vaccines. Vaccine 23: 1209-1224.
13. Baena A, Porcelli S.A. (2009) Evasion and subversion of antigen presentation by Mycobacterium tuberculosis. Tissue Antigens 74: 189-204.
14. Grode L, Seiler P, Baumann S., Hess J, Brinkmann V, et al (2005) Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guerin mutants that secrete listeriolysin. J Clin Invest 115: 2472-2479.
15. Sun R, Skeiky YA, Izzo A, Dheenadhayalan V., Imam Z, et al. (2009) Novel recombinant BCG expressing perfringolysin O and the over-expression of key immunodominant antigens; pre-clinical characterization, safety and protection against challenge with Mycobacterium tuberculosis. Vaccine 27: 4412-4423.
16. Sadagopal S, Braunstein M, Hager C.C., Wei J., Daniel AK, et al. (2009) Reducing the activity and secretion of microbial antioxidants enhances the immunogenicity of BCG. PLoS One 4: e5531.
17. Bendelac A, Savage PB, Teyton L. (2007) The biology of NKT cells. Annual review of immunology 25: 297-336.
18. Im JS, Arora P, Bricard G., Molano A, Venkataswamy MM, et al (2009) Kinetics and cellular site of glycolipid loading control the outcome of natural killer T cell activation. Immunity 30: 888-898.
19. Brigl M, Bry L, Kent S.C., Gumperz JE, Brenner M.B. (2003) Mechanism of CD1d-restricted natural killer T cell activation during microbial infection. Nature immunology 4: 1230-1237.
20. Behar SM, Porcelli S.A. (2007) CD1-restricted T cells in host defense to infectious diseases. Current topics in microbiology and immunology 314: 215-250.
21. Hermans IF, Silk JD, Gileadi U, Salio M., Mathew B, et al. (2003) NKT cells enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells. Journal of immunology 171: 5140-5147.
22. Fujii S, Motohashi S, Shimizu K., Nakayama T, Yoshiga Y, et al (2010) Adjuvant activity mediated by iNKT cells. Semin Immunol 22: 97-102.
23. Fujii S, Shimizu K, Smith C., Bonifaz L, Steinman R.M. (2003) Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein. The Journal of experimental medicine 198: 267-279.
24. Cerundolo V, Barral P, Batista F.D. (2010) Synthetic iNKT cell-agonists as vaccine adjuvants-finding the balance. Curr Opin Immunol 22: 417-424.
25. Galli G, Pittoni P, Tonti E., Malzone C, Uematsu Y, et al (2007) Invariant NKT cells sustain specific B cell responses and memory. Proc Natl Acad Sci U S A 104: 3984-3989.
26. Huang Y, Chen A, Li X., Chen Z, Zhang W, et al (2008) Enhancement of HIV DNA vaccine immunogenicity by the NKT cell ligand, alpha-galactosylcer-amide. Vaccine 26: 1807-1816.
27. Li X, Fujio M, Imamura M., Wu D, Vasan S, et al (2010) Design of a potent CD1d-binding NKT cell ligand as a vaccine adjuvant. Proc Natl Acad Sci U S A 107: 13010-13015.
28. Venkataswamy MM, Baena A, Goldberg M.F., Bricard G., Im JS, et al. (2009) Incorporation of NKT cell-activating glycolipids enhances immunogenicity and vaccine efficacy of Mycobacterium bovis bacillus Calmette-Guerin. J Immunol 183: 1644-1656.
29. Singh AK, Gaur P, Das S.N. (2014) Natural killer T cell anergy, co-stimulatory molecules and immunotherapeutic interventions. Hum Immunol 75: 250-260.
30. Li X, Chen G, Garcia-Navarro R, Franck R.W., Tsuji M. (2009) Identification of C-glycoside analogues that display a potent biological activity against murine and human invariant natural killer T cells. Immunology 127: 216-225.
31. Padte NN, Boente-Carrera M, Andrews C.D., McManus J., Grasperge BF, et al. (2013) A glycolipid adjuvant, 7DW8-5, enhances CD8+ T cell responses induced by an adenovirus-vectored malaria vaccine in non-human primates. PLoS One 8: e78407.
32. Arora P, Venkataswamy MM, Baena A, Bricard G., Li Q, et al. (2011) A rapid fluorescence-based assay for classification of iNKT cell activating glycolipids. J Am Chem Soc 133: 5198-5201.
33. Padte NN, Li X, Tsuji M., Vasan S. (2011) Clinical development of a novel CD1d-binding NKT cell ligand as a vaccine adjuvant. Clin Immunol 140: 142-151.
34. Wen X, Rao P, Carreno L.J., Kim S., Lawrenczyk A, et al. (2013) Human CD1d knock-in mouse model demonstrates potent antitumor potential of human CD1d-restricted invariant natural killer T cells. Proc Natl Acad Sci U S A 110: 2963-2968.
35. Arora P, Baena A, Yu K.O., Saini NK, Kharkwal SS, et al. (2014) A single subset of dendritic cells controls the cytokine bias of natural killer T cell responses to diverse glycolipid antigens. Immunity 40: 105-116.
36. Arora P, Foster EL, Porcelli S.A. (2013) CD1d and natural killer T cells in immunity to Mycobacterium tuberculosis. Adv Exp Med Biol 783: 199-223.
37. Kiepiela P, Ngumbela K, Thobakgale C., Ramduth D, Honeyborne I, et al (2007) CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat Med 13: 46-53.
38. Reynolds MR, Rakasz E, Skinner P.J., White C., Abel K, et al. (2005) CD8+ T-lymphocyte response to major immunodominant epitopes after vaginal exposure to simian immunodeficiency virus: too late and too little. J Virol 79: 9228-9235.
39. Dhodapkar MV (2009) Harnessing human CD1d restricted T cells for tumor immunity: progress and challenges. Front Biosci (Landmark Ed) 14: 796-807.
40. Giaccone G, Punt CJ, Ando Y, Ruijter R., Nishi N, et al. (2002) A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors. Clin Cancer Res 8: 3702-3709.
41. Parekh VV, Wilson MT, Olivares-Villagomez D, Singh A.K., Wu L., et al. (2005) Glycolipid antigen induces long-term natural killer T cell anergy in mice. J Clin Invest 115: 2572-2583.
42. Van Kaer L., Parekh VV, Wu L. (2011) Invariant NK T cells: potential for immunotherapeutic targeting with glycolipid antigens. Immunotherapy 3: 59-75.
43. Venkataswamy MM, Porcelli S.A. (2010) Lipid and glycolipid antigens of CD1d-restricted natural killer T cells. Semin Immunol 22: 68-78.
44. Li X, Shiratsuchi T, Chen G., Dellabona P, Casorati G, et al (2009) Invariant TCR rather than CD1d shapes the preferential activities of C-glycoside analogues against human versus murine invariant NKT cells. J Immunol 183: 4415-4421.
45. Schmieg J, Yang G, Franck R.W., Tsuji M. (2003) Superior protection against malaria and melanoma metastases by a C-glycoside analogue of the natural killer T cell ligand alpha-Galactosylceramide. J Exp Med 198: 1631-1641.
46. Wu TN, Lin KH, Chang Y.J., Huang JR, Cheng JY, et al. (2011) Avidity of CD1d-ligand-receptor ternary complex contributes to T-helper 1 (Th1) polarization and anticancer efficacy. Proc Natl Acad Sci U S A 108: 17275-17280.
47. Quinn KM, Da Costa A, Yamamoto A, Berry D., Lindsay RW, et al. (2013) Comparative analysis of the magnitude, quality, phenotype, and protective capacity of simian immunodeficiency virus gag-specific CD8+ T cells following human-, simian-, and chimpanzee-derived recombinant adenoviral vector immunization. J Immunol 190: 2720-2735.
48. Abbink P, Lemckert AA, Ewald B.A., Lynch DM, Denholtz M, et al. (2007) Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J Virol 81: 4654-4663.
49. Patel O, Cameron G, Pellicci D.G., Liu Z., Byun HS, et al. (2011) NKT TCR recognition of CD1d-alpha-C-galactosylceramide. J Immunol 187: 4705-4713.
50. Yu KO, Im JS, Molano A, Dutronc Y., Illarionov PA, et al. (2005) Modulation of CD1d-restricted NKT cell responses by using N-acyl variants of alpha-galactosylceramides. Proc Natl Acad Sci U S A 102: 3383-3388.
51. Lutz MB, Kukutsch N, Ogilvie A.L., Rossner S., Koch F, et al. (1999) An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods 223: 77-92.